BioSpace News Archive

Approval for the combination treatment was based on results from the Phase I/II CheckMate-040 trial in which Opdivo and Yervoy showed an overall response rate of 33% in this patient population.

Cell Medica has rebranded itself as Kuur Therapeutics as it dives into the development of anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell therapy platform.

Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.

The demand within the global market for clinical laboratory services has been rising on account of advancements in the field of medical research.

The global healthcare IT market is brimming with opportunities as health information technology has revolutionized patient care and healthcare services across the world.

Over the last decade, the demand for prefilled syringes has increased significantly.

The global personal mobility devices market is driven due to aging conditions that leads to bone density and mobility.

The global biotechnology market is mainly driven by the surge in the demand for food, depleting natural resources, government regulatory support, and technological advancements of various solutions to counter fatal diseases.

Increasing geriatric population and growing neurological, orthopedic, and ENT disorders are will expand the global surgical navigation system market.

Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the “Offers”) to purchase any and all of the outstanding $42,465,000 in aggregate principal amount of its 2.50% Senior Convertible Notes due 2021 (CUSIP: 249908AA2) and $34,522,000 of its 5.00% Senior Convertible Notes due 2024 (CUSIP: 04545LAA5) (together, the “Notes”).